Biophytis announces the publication of its parent company financial statements for the fiscal year ended December 31, 2025, prepared in accordance with French accounting rules and principles and approved by the Board of Directors on July 24, 2026, as well as the resumption of trading of its shares on Euronext Growth Paris.
The annual financial statements were the subject of a report by the statutory auditors stating that they were unable to issue an unqualified opinion, based in particular on uncertainties regarding the Company’s going concern status and the accounting treatment of certain capital transactions described in their report.
This publication complies with the Company’s obligations as an issuer on Euronext Growth, given the limited size of its group (total assets of less than €20 million, fewer than 250 employees, and no revenue for any of the group’s entities).
Although the scope differs from that of the IFRS consolidated financial statements published in 2024, and although the final 2025 data are not directly comparable, this presentation remains faithful to the Company’s economic reality and complies with Article L. 233-16 of the French Commercial Code.
